ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1714

Can We Predict Early Relapses in Adult IgA Vasculitis?

Jaka Ostrovrsnik1, Ziga Rotar 1, Matija Tomsic 1 and Alojzija Hocevar 1, 1Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: IgA vasculitis, relaps and Predictor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In adults, IgA vasculitis (IgAV) frequently takes a severe course in the acute phase of the disease. Data on long term outcomes is limited. It has been observed that a proportion of patients relapse. Our aim was to define potential predictors of relapsing IgAV in a cohort of unselected adult IgAV cases.

Methods: We analysed medical records of histologically proven IgAV cases diagnosed between January 2010 and September 2018, and prospectively followed until May 2019. The relapse was defined as a new development of skin purpura, joint or gastrointestinal tract (GIT) symptoms or laboratory signs of renal disease at follow-up visit after clinical/laboratory remission, after exclusion of other causes. We explored the differences in the baseline characteristics between the relapsing and non-relapsing IgAV cases. A multivariate logistic regression model included predictors that significantly differed between the groups.

Results: During the 105-month observation period we identified 250 new IgAV cases. During the acute disease 4 patients died. 33 patients were lost to follow-up. Of the remaining 213 patients who were followed for a median 12.5 (IQR 6.8–24.2) months, 30 (14.1%) patients relapsed. 21 (70%), 5 (16.7%), and 4 (13.3%) patients relapsed once, twice, and three or more times, respectively. The relapse was limited to the skin in 24 (80%) patients, involved skin, joints, GIT and kidneys in 4 (13.3%), and was limited to the kidneys in 2 (6.7%) patients. The comparison of baseline characteristics between relapsing and non-relapsing IgAV subgroup is shown in Table 1.  In a multivariate logistic regression model, the relapsing IgAV was associated with younger patient age (OR 0.98 (95% CI 0.96-0.99; p=0.024) and non-smoking status (OR 4.41 (95%CI 1.6-12.1), p=0.004).

Conclusion: Younger IgAV patients, who never smoked, tend to have a higher risk for early relapse and should be followed closely.


Disclosure: J. Ostrovrsnik, None; Z. Rotar, None; M. Tomsic, None; A. Hocevar, None.

To cite this abstract in AMA style:

Ostrovrsnik J, Rotar Z, Tomsic M, Hocevar A. Can We Predict Early Relapses in Adult IgA Vasculitis? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/can-we-predict-early-relapses-in-adult-iga-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-we-predict-early-relapses-in-adult-iga-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology